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Mixing the Old with the New
Chinese Traditional Medicine and
The Regulation of Food and Drugs in the United
States
Introduction
The practice of traditional Chinese healing methods has secured a small but
noticeable foothold in some sectors of American society. Whether this is simply
yet another incarnation of the West's centuries-old romantic obsession with the
exotic lure of the East, or a reserved but genuine concession to the virtues of a
foreign medical discipline remains unclear. The purpose of this paper is to study
the economic signicance of Chinese traditional medicine and its implications
for the American pharmaceutical industry and United States food and drug
regulation.
PART I: THE CASE FOR ACTIONEnter the Dragon:
The Importance of the Chinese Market
American industry unabashedly considers East Asia, particularly China, as the
world's next great consumer market1. This is especially so as regards health
care - with a population of approximately 1.24 billion2, China is fourfold as
1National Trade Data Bank, U.S. Department of Commerce,
Report on China - Leading Sectors for U.S. Exports and Investment, September
23 1999. See http://www.tradeport.org/ts/countries/china/sectors.html.
2CIA World Factbook 1999. See http://www.odci.gov/cia/publications/factbook/ch.html.
1populous as the United States { and that population is an aging one. Lacking
a developed domestic health care infrastructure, China is fertile ground for eco-
nomic colonialism, both in terms of exports of American medical products to,
and the location of American production facilities within, China. Notwithstand-
ing notable regulatory restrictions, the U.S Government's Country Commercial
Guide for the Fiscal Year 1999 for the People's Republic of China3 advises:
All of these measures pose a challenge to the foreign pharmaceutical importer
or foreign domestic producer. Prot margins are considered slim, and most
companies currently in the market place concentrate on niche markets where
they may have up to a ninety-percent market share. Even so, the shear (sic)
size of the \potential" market, as well as impressive growth numbers (estimated
to be fteen percent annually into the next decade) makes the Chinese market
dicult to ignore.
Even assuming a market free of government regulation, however, American
pharmaceutical companies will face two signicant barriers to entry, namely the
relatively high cost of drugs and lack of Chinese consumer knowledge about
Western medical science and treatments. The most formidable challenge facing
these companies today is how to address the signicant economic and educa-
tional disparities between the United States and East Asia.
3U.S Government Country Commercial Guide FY 1999: Peo-
ple's Republic of China. The Guide is available online at
http://www.state.gov/www/about state/business/com guides/1999/eastasia/china99 05.html.
2A Tale of Two Countries: Contrasting American and Chi-
nese Healthcare
The American healthcare industry is riding the crest of a huge wave of medi-
cal research and technological advancement. For the American healthcare pa-
tient this means more sophisticated and eective drugs and medical procedures.
Aggressive advertising and promotion of these new developments continue to
elevate the average consumer to new heights of medical self-awareness and in-
formation of treatment options, to the point where the range of choices available
to the consumer may be conservatively described as bewildering.
These developments, however, have not come cheaply. Medical treatment
now costs more than it ever has before. For example, the price of prescription
drugs increased by 172% between 1982-1984 and the second quarter of 19994.
Medical care costs in general increased 154% between 1982-1984 and November
19995. By contrast, consumer prices for food and beverages between 1982-1984
and November 1999 increased only 65.8% and transportation only 47.2%6. Of
the US$1.09 trillion total national health expenditure in 1997, $348 billion was
borne by insurance companies and $507 billion by State and Federal government.
Excluding taxes, the actual healthcare consumer directly bore only $187 billion
of total expenditure or about 17 cents to the dollar7.
4Health Care Financing Administration, U.S. Department of
Health and Human Services, Index Levels of Medical Prices. See
http://www.hcfa.gov/stats/indicatr/tables/t08.htm.
5United States Consumer Price Index. This is available at various sources including
http://www.bsu.edu/business/bbr/IBB/US/pcpi/pcpi.htm
6Ibid.
7Health Care Financing Administration, U.S. Department of Health and Human
Services National Health Expenditures, by Source of Funds and Type of Expenditure: Selected Calendar Years 1992-97.
See http://www.hcfa.gov/stats/nhe-oact/tables/t11.htm.
3China is a study in opposites. The majority of China's population resides
in rural areas and has only basic schooling. There is little, if any, exposure
to Western medical science, treatments or procedures. The rural populace is
also desperately poor. While American consumers bore only a fraction of their
total medical expenditures, Chinese consumers lack comparable resources to pay
even for that fraction. China's per capita GDP in 1998 was estimated at $3,600
compared to $31,000 for the United States in the same year8.
Chinese consumers spend comparatively less (in terms of percentage share of
GDP) on health care than American consumers. Total pharmaceutical exports
from the United States to China in 1998 exceeded $477m, almost a third of
total Chinese pharmaceutical imports at $1.72 billion. Total imports, however,
accounted for a scant 12.46% of the Chinese pharmaceutical market in 1999,
which, though totaling $13.8 billion9, constituted only 0.31% of total GDP of
$4.42 trillion10. Although it was not possible to nd same-source data to form
an accurate comparison, the Department of Commerce's Bureau of Economic
Analysis reported11 the GDP of the United States' in 1998 as totaling $8.76
trillion; of which medical care constituted $910 billion. A dierent report12
estimated total health care expenditure in 1997 at $1.09 trillion, of which ex-
penditure on \drugs and other medical nondurables" totaled $108.9 billion or
1.24% of the 1998 GDP { exactly fourfold that of China in percentage terms.
8CIA World Factbook 1999
9U.S Government Country Commercial Guide FY 1999: People's Republic of China
10CIA World Factbook 1999
11Bureau of Economic Analysis, U.S. Department of Commerce, News Release, De-
cember 22, 1999. See http://www.bea.doc.gov/bea/newsrel/gdp399f.htm
12Ante. See footnote 7.
4Given that China's GDP is less than twice that of the United States, it
is perhaps unsurprising that a country four times as populous as the United
States spends comparatively four times less on health care. This phenomenon is
undoubtedly compounded by the severe lack of private funding (whether through
insurance or otherwise) for healthcare services, for the country in general and
for rural areas in particular. In a keynote speech13 given at Beijing Medical
University shortly after taking oce as Director-General of the World Health
Organization, Dr Gro Harlem Brundtland stressed the lack of comprehensive
insurance schemes for the nancing of preventive care in China. In particular,
she emphasized the importance of extending social insurance to the families of
those covered under state schemes (such as civil servants and workers) and other
sectors of society, such as those in rural areas, who are not covered at all. The
dearth of healthcare practitioners and the sheer logistical diculties of providing
healthcare infrastructure to rural areas complicate the problem further.
The Price Isn't Right: Challenges for American Industry
Poor consumer information, low income levels and an absence of private funding
have stied demand for expensive Western drugs, aording a partial explana-
tion for the insubstantial penetration of foreign pharmaceuticals in China. One
response of American pharmaceutical companies might be to focus its energies
on the only course genuinely within its control: convince Chinese consumers of
the superior value and potency of Western medications, notwithstanding their
13The full text of the speech is available on WHO's website at
http://www.who.int/director-general/speeches/english/19981123 beijingbmu.html
5higher prices, by educating them about Western scientic methods. However,
as recently as in 1998 the State Department's United States Foreign and Com-
mercial Service (\USFCS") published a report14 acknowledging that:
Price vs. cost will probably remain one of the most important considera-
tions in [the Chinese pharmaceutical] market. Some leading U.S research-based
pharmaceutical rms have found this market to be less than receptive to their
newest { and priciest { cutting-edge products.
It is likely that American pharmaceutical companies will also nd them-
selves up against opposition of a substantially dierent kind. Healthcare costs
are borne primarily by the Chinese government through a State-run healthcare
regime that presents further barriers to entry. Medical expenses have up till now
been paid for by the government or treatment has been provided by state-owned
enterprises. The government also publishes a National Essential Drug Bulletin,
which lists those drugs for which the state will reimburse consumers. In the
interests of protecting domestic industry and promoting a healthy balance of
trade, the only foreign drugs which are listed are those for which there is no
domestic substitute. Although a new urban insurance scheme was introduced in
1999 under which enterprises will make contributions to medical insurance and
a general medical fund for employees, the scheme does not cover dependants or
the rural sector15.
14Bruce Quinn, United States Foreign and Commercial Ser-
vice, U.S. State Department, Drugs & Pharmaceuticals, (1998). See
http://www.corporateinformation.com/data/statusa/china/chinapharmaceutical.html
15Nancy Xu, United States Foreign and Commercial Service, U.S.
State Department, New Urban Medical Insurance System, (1999). See
6Now It's Time for Double Jeopardy: Traditional Chinese
Medicine
Even if these diculties can be circumvented, American pharmaceutical com-
panies will face the uphill task of combating cultural resistance to their prod-
ucts. Market penetration is crucially dependent on the substitution of Ameri-
can brand names for traditional Chinese remedies in the minds and wallets of
Chinese consumers. These traditional remedies take two forms, both of which
are relevant to the discussion that follows. The rst is dispensed by the village
healer, a master of traditional Chinese medicine, trained through apprenticeship
in the ways of an ages-old medical philosophy. For a nominal fee he diagnoses
the patient's spiritual and elemental as well as physical health. His living is
made o the sale, from his personal stock, of made-to-measure raw herbal ma-
terials - medicinal remedies for preparation and administration by the patient
or his family in his home. These \herbs" may include both animal and plant
products, including spices, roots, plants, and even insects. Because of the per-
sonal interaction and communal spirit that characterizes these transactions, this
is in many ways akin to medication prescribed by family doctors in the West,
although as will be seen, the approach to the diagnosis and treatment of illnesses
is starkly dierent.
The second form of traditional medicine is distributed by Chinese state-
owned pharmaceutical enterprises that have utilized the technological advance-
ments of the 20th century to formulate tablets, capsules and mixtures of these
http://www.tradeport.org/ts/countries/china/mrr/mark0119.html.
7botanical combinations for commercial distribution. These pre-packaged medicines
constitute the bulk of Chinese pharmaceutical exports and are readily available
throughout East Asia.
Centuries of tradition and culture have ingrained the holistic, philosophical
character of Chinese medicinal practice into the purchasing decisions of Chinese
consumers worldwide. Both forms of traditional healing remain popular not only
in China, but Japan, Hong Kong, Taiwan, Singapore and among traditional
Chinese in the United States. For example, a September 1996 World Health
Organization (WHO) Fact Sheet on Traditional Medicine reported that Japan
experienced a 15-fold increase in \kampoh", or Chinese-method herbal prepara-
tions compared with a 2.6-fold increase in the sales of mainstream pharmaceu-
tical products16. In October 1995, the Singapore Ministry of Health Committee
on Traditional Chinese Medicine reported that about 12% of all outpatient at-
tendance is overseen by practitioners of traditional Chinese medicine17.
Within China, the projected growth gures are astonishing. The 1996 WHO
Fact Sheet18 reports herbal preparations as accounting for 30-50% of total
medicinal consumption in China. That trend appears likely to continue. A
United States Department of Commerce USFCS report on the dietary supple-
ments market in China published on 1 August 1999 estimates that the health
foods industry in China (which includes dietary supplements) is currently worth
16World Health Organization Fact Sheet No 134. See
http://www.who.int/int-fs/en/fact134.html
17An Executive Summary of the report is available at
http://www.gov.sg/moh/mohiss/tcm/tcmrpt.html
18Ante. See Footnote 16.
8$2.4-3.6 billion and may expand to as much as $12.1 billion by 201019. The re-
port emphasizes that Chinese consumers' demand for products with curative or
health enhancing eects prompted a 30-fold increase in the number of Chinese
dietary supplement suppliers between 1992 and 199920. A 1998 USFCS report21
outlines the challenges facing the pharmaceutical industry in approaching the
Chinese market. Signicantly, it ranks health foods and supplements on par
with over the counter drugs as having the greatest growth potential for Ameri-
can exports.
The good news is that this appears to match trends within America. An
FDA Report22, updated in January 1999, cites growth of dietary supplement
sales in the United States as having risen from $3.3 billion to $6.5 billion be-
tween 1990 and 1996. These reports may give American dietary supplement
manufacturers reason to expect not only an increase in domestic sales, but also
increased exports of American dietary supplement products to China, replicat-
ing overseas the domestic turf war between pharmaceutical companies and the
dietary supplements industry. The bad news for American enterprise is that
the USFCS report on the dietary supplements market in China estimates that
Chinese manufacturers dominate 80 to 90 percent of the Chinese market. The
argument advanced here is that the vice-like grip of these domestic enterprises
19Lily Chou & Xianmin Xi, United States Foreign and Commer-
cial Service, U.S. State Department, Dietary Supplements, (1999). See
http://www.tradeport.org/ts/countries/china/isa/isar0011.html
20Ante. See footnote 1.
21Ante. See footnote 14.
22Paula Kurtzweil, Food and Drug Administration, U.S. Department of Health and
Human Services, An FDA Guide to Dietary Supplements, 1998-1999. An online ver-
sion is available at http://www.fda.gov/fdac/features/1998/598 guid.html
9over the Chinese market is unlikely to loosen without rst, serious reconsidera-
tion of existing corporate strategy and second, substantial legislative reform in
America.
Whereas one may interpret upward trends in the United States dietary sup-
plements market as a preference by higher-income American consumers23 for
luxury medical products, it is dicult to extend the same analysis to China.
It is my case that for the economic, educational, political and cultural reasons
that have been discussed, locally produced traditional remedies may continue
to form the rst-choice remedy amongst Chinese consumers. For American
pharmaceutical companies the ercest competition will not come from the di-
etary supplements industry or unaordable high priced European alternatives,
but from more familiar low cost domestic botanical remedies, manufactured by
state-owned or recently privatized enterprises operating under the umbrella of
the Chinese government protectionist policies. The 1999 USFCS report24 on
the dietary supplements market in China cautions:
The history of trust in Traditional Chinese Medicines (TCM's) has driven
[Chinese] consumers to readily accept herbs and other natural products, paving
the road for success of the health food industry. Health foods are now playing
a role previously lled by TCM's, addressing problems ranging from high blood
23Center for Food Safety and Applied Nutrition, Food and Drug
Administration, U.S. Department of Health and Human Services,
Economic Characterization of the Dietary Supplement Industry Final Report,
(March 1999) Section 4.2.1. The report cites a 1990 report by Subar and Block
nding that the incidence of dietary supplement consumption was highest amongst
high school and college graduates and increased with income. See
http://vm.cfsan.fda.gov/comm/ds-econt.html.
24Ante. See footnote 19.
10cholesterol to weight gain to aging. Furthermore, mass-marketing has lent health
foods an air of legitimacy that TCM's never had with handsome packaging and
clearly dened product functions.
Says WHO? International Views on Traditional Medicine
The domestic Chinese pharmaceutical industry is highly unregulated and
diers signicantly from that of the United States. The 1998 USFCS report
cites numerous factories as producing copyright or trademark infringing coun-
terfeit drugs. Of more direct concern as far as human health is concerned,
production standards fall short of acceptable levels: the same report cites only
18 of over 4000 pharmaceutical factories as meeting Good Manufacturing Prac-
tice standards25. There is no reason to believe that factories manufacturing
traditional Chinese medicines fare any better. A further concern pertaining to
the traditional medicine (dietary supplement) industry is what would consti-
tute \misbranding" under United States law. Many medicines are marketed
claiming the ability to address a wide range of medical ailments. Some claims
are medicinally accurate, but simply unproven by Western methods; others are
downright questionable.
Notwithstanding these concerns, traditional medicine continues to enjoy
strong endorsement by the World Health Organization, an approach that varies
markedly from that of the U.S. Food & Drug Administration (\FDA"), which
is discussed below. There are three possible reasons for this dierence. First,
25Non-compliance with GMP standards constitutes unlawful adulteration under 21
U.S.C. x 351(a)(1)(B) of the 1938 Food, Drugs and Cosmetics Act.
11WHO recognizes the economic barrier between third world citizens and Western
medication - many of those whose health the organization addresses can only
aord traditional remedies. Secondly, as an organization of the United Nations,
it has a necessarily accommodating, internationalist, culture, and does not play
favorites to Western medical science. Thirdly, unlike the FDA, it is not subject
to lobbying and political pressure from the sizable U.S. domestic pharmaceutical
industry.
In May 1998, the 51st World Health Assembly in Geneva adopted a resolution
urging WHO Member States \to develop and implement national plans of action
or programmes (sic) on indigenous people's health while \respecting, preserv-
ing and maintaining the knowledge of traditional healing and medicine in close
cooperation with indigenous people26. Following the appointment of the cur-
rent Director-General, Dr Brundtland, WHO underwent restructuring, in which
a specic Essential Drugs and Medicines (EDM) team on traditional medicine
was established to research policy on traditional remedies27. More specically,
WHO's Special Programme (sic) for Research & Training in Tropical Diseases
(TDR) endorsed the importance of traditional medicines in tropical disease re-
search. Having determined that several important classes of anti-malarial drugs
originate from plant products identied in traditional medicine, it now seeks to
further research into traditional medicine in the hope of discovering new lead
compounds for other diseases28.




12Wheel of Fortune:The Market for Traditional Chinese Medicine in the United States
Ironically, this modicum of international recognition may have done just
enough to legitimize Chinese traditional medicine in the minds of Western con-
sumers, drawing it in from the lunatic fringe of medical quackery. Yet, the lack
of rm endorsement by the mainstream Western medical community dresses it
with the mystique that appeals so strongly to archetypal dietary supplement
enthusiasts. New discoveries and conicting laboratory studies have created a
sense of uncertainty in modern medical science. In turn, this perceived lack
of consensus among mainstream medical experts pronounces the frustration of
educated, higher income consumers who feel disillusioned with the high cost
of health care, and its focus on curative (as opposed to preventive) medicine.
That sense of frustration has driven these consumers to search for alternative
remedies that they feel may be eective even though clinically unproven.
Ironically, then, notwithstanding its lack of endorsement by the Western scientic community, demand for Chinese traditional medicine in the West appears to be growing more steadily than demand for Western medicine in China, a fact that has been reected through government legislative and regulatory activity. As of July 10 1998, 35 jurisdictions within the United States (34 states plus the District of Columbia) had passed laws regulating oriental medicine and acupuncture. In 1998, the FDA reclassied single-use acupuncture needles as Class II medical devices from their hitherto Class III status under the 1938 Food, Drugs and Cosmetics Act (\FDCA"). In its press release29, the FDA explained that:
As part of this reclassication, FDA has determined that the current in-
vestigational use labeling requirements no longer apply to acupuncture needles
intended for general use by qualied practitioners.
A Reuters Health Information30 article dated October 26, 1999 on the Amer-
ican Medical Association's 18th Annual Science Reporters Conference suggests
that unreported self-treatment using Chinese traditional medicine alongside con-
29See http://www.fda.gov/bbs/topics/ANSWERS/ANS00722.html
30See www.reutershealth.com. Unfortunately, Reuters Health Information
only keeps articles for 10 days. A copy of the report is available at
http://www.acupuncture.com/News/Reuters Health NY.htm.
13ventional remedies has reached the point where medical practitioners ought to
be concerned about possible incompatibility with prescription drugs31. The
same article cites the following US National Institutes of Health statistics: 40%
of US citizens say they used some form of alternative medicine in 1997, with
total US spending on alternative medicine practitioners exceeding $21.2 billion.
Demand for Oriental health food products has also increased. Soyatech Inc,
a research company for the soybean industry, estimated the soybean product
market to be worth $1 billion in 1997 and growing at 20% annually in 1999 com-
pared to 5% for mainstream foods32. That projection now appears conservative
in light of the FDA's announcement on 26 October 1999 that it now permits
claims relating to coronary heart disease (\CHD") in connection with soybean
products. The FDA nally concluded that foods containing soy protein included
in a diet low in saturated fat and cholesterol might reduce the risk of CHD by
lowering blood cholesterol levels. As a marker point for arguments made later
in this paper, it should be noted here that the nutritional value of soy products
has been a given in East Asia for centuries.
In conclusion, Chinese traditional medicine is economically signicant for Amer-
ican companies in two respects. First, within the Chinese and Japanese mar-
kets, and to a lesser but still notable extent in other parts of East Asia, it is
the predominant competitor with Western pharmaceuticals for consumer health
expenditure. Levels of American pharmaceutical exports to China remain low
31The problem has sparked litigation. See Product Watch,
3 No. 18 Mealey's Litig. Rep.: Drugs & Med. Devices 24
32Soyatech Inc, Soya and Oilseed Bluebook Update Vol 6 Issue 4 (October-
December 1999)
14notwithstanding the fact that low production standards in Chinese factories have
given American-made pharmaceuticals an exceptional reputation for quality.
Particularly because of income levels, American pharmaceutical products are
likely to remain unpopular, delaying or preventing establishment of widespread
brand name recognition in the short term. Given the recommendation made
in the 1998 USFCS report on Drugs and Pharmaceuticals in China33 that \a
`Made in USA' designation may well lead to greater sales", closer examina-
tion of the Chinese traditional medicine industry, including the development of
American-made substitutes, may be one strategy worth careful consideration.
Secondly, the popularity of Chinese traditional medicine within the United
States justies greater research into the validity of preventive and curative
claims. In 1992, the National Institutes of Health established the National
Center for Complementary and Alternative Medicine (NCCAM). According to
the NCCAM web site,
The Congressional mandate establishing the NCCAM stated that the Cen-
ter's purpose is to facilitate the evaluation of alternative medical treatment
modalities to determine their eectiveness.
Verication of such claims will undoubtedly stimulate demand, in which
event products developed for Chinese consumers may nd a secondary market
in the United States.
It's time for American pharmaceutical companies to take stock. The di-
33Ante. See footnote 14.
15etary supplement industry at home has grown too economically and politically
powerful to be conveniently ignored. Turning a Nelsonian blind eye to the
vast potential foreign market for traditional remedies will only contribute to
the redistribution of power that has taken place in the last 30 years. Only
by re-assessing the true value of their vested interests in the status quo can
pharmaceutical companies avail themselves of new possibilities waiting in the
wings. Chinese traditional medicine may be the booster shot the industry so
badly needs and it's certainly an attractive candidate as a catalyst for change:
the market is huge and it has millennia of pre-clinical study. This necessitates
reconsideration of the current regulatory structure, both in terms of the unre-
alistic demands it places on the FDA and the incompatibility of the FDCA's
conceptual basis with the pressures of an increasingly integrated world economy.
PART II: LEGAL AND REGULATORY ISSUES
The passing of the Dietary Supplement Health and Education Act in 1994
(\Dietary Supplements Act") marked the advent of a day of reckoning between
the pharmaceutical industry and the alternative medicine community. The clear
signal to Congress was this: American consumers believe that the legislative
structure for the regulation of new drugs has failed. In the context of Chinese
traditional medicine, the principal defects are these. First, the system of prod-
uct classication, which dates back to 1938, and method of claims-verication,
instituted by the 1968 Amendments to the FDCA, both strongly favor curative
over preventive medicine. Second, the approval cycle for new drugs takes too
16long and results in unrealistically expensive products.
Hobson's Choice: Classication Issues Under Existing Legislation
The rst diculty is one of denition { how do we determine the applica-
ble regulatory scheme to Chinese traditional medicine? The FDCA's approach,
which is to distinguish between food and drugs on the basis of intended use, is
perforated with ambiguities that, while investing the FDA with enormous regu-
latory discretion, provide little guidance for articles, such as Chinese traditional
medicines, that defy easy classication.
\
Food" is dened as including \articles used for food or drink for man34";
\drugs" are dened as including \articles intended for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease in man35" and \articles...intended
to aect the structure or any function of the body of man36". While there are
easy cases, such as the classication of synthetic pain relieving substances like
Ibuprofen, the active ingredient in Advil, as drugs, there are also dicult ones.
With the exception of the proviso to x 321(g)(1)(c) pertaining to articles
aecting structure and function, the denitions of \food" and \drug" are not
mutually exclusive. It is possible for an article satisfying the denitions of both
food and drug. Common table salt is one example: it may be used as food when
used as avoring, or as a salt when used as an antiseptic. When used as a food
3421 U.S.C. x 321(f)(1)
3521 U.S.C. x 321(g)(1)(B)
3621 U.S.C. x 321(g)(1)(C)
17preservative, it may be both, for it is not only intended to be ingested when the
food is taken, but intended to keep the food from decomposing, thus \intended
for use in the...prevention of disease in man". We only avoid the conundrum
because common table salt is common enough that it is generally recognized as
safe (and eective), and avoids having to comply with regulatory requirements
relating to disease-related claims.
But how do we treat Chinese traditional medicines, say herbal soup prepara-
tions, which are primarily intended to cure, treat or prevent disease, but which
may be intended to be taken as part of a meal? Being unpleasant to taste, the
preparation may be prepared with \superuous" ingredients such as chicken or
pork to grease the palate for its ingestion. To cast the dilemma in more familiar
terms, when Walt Disney penned the marvelous counsel of the childhood c-
tional character Mary Poppins that \a spoonful of sugar makes the medicine go
down37" did she intend that the sugar become part of the nasty syrup, or did
the syrup become part of a tasty treat? It may not have occurred to the noto-
rious nanny, but the distinction is crucial: classication as a drug invokes the
pre-market approval procedures for new drugs. Classication as a food restricts
the types of claims that may be made in relation to the product.
Yet another diculty lies within the \food" classication itself. It is not
always clear how to determine whether to classify Chinese traditional medicines
as food or a sub-category of foods, dietary supplements. The relevant parts of
37The book, published by British author P. L. Travers, in 1934, narrates the scene
popularized in the lm musical, but the catchphrase is that of brothers Richard M. and
Robert B. Sherman, who wrote the music for the 1964 movie and received Academy
Awards for Best Musical Score that year. Curiously, the modern provisions of the
FDCA preceded the movie by only two years, in 1962.
18the FDCA's denition of dietary supplements read as follows38:-
The term \dietary supplement" means a product...intended to supplement
the diet that bears or contains one or more of the following dietary ingredients:
...
(B) a mineral,
(C) an herb or other botanical
...
The denition also includes products labeled as dietary supplements meant
to be taken in capsule or tablet form which are not represented for use as
conventional food or as a sole item of a meal or diet39. Products which are
labeled as dietary supplements but which are not taken in capsule or tablet
form and which are not represented as conventional food or use as a sole item of
a meal or of a diet are also included in the denition40. The FDCA only permits,
in relation to the sale of dietary supplements, claims relating to classical nutrient
deciency and structure/function claims41.
As a matter of statutory interpretation, the FDA's classication of herbs
and herb extracts sold in capsule, tablet or liquid form as dietary supplements
is less problematic than other types of traditional medicine. Where, however,
herbs are sold in combination { either pre-packaged or tailor-made by the ori-
3821 U.S.C. x 321()(1)
3921 U.S.C. x 321()(2)(A)(i)
4021 U.S.C. x 321()(2)(A)(ii)
41x 343(r)(6)(A)
19ental medicine practitioner { for preparation as a soup, they bear resemblance
to instant food products that are not regarded as dietary supplements. The in-
structions are similar: add water, boil 30 minutes, drink. The FDA's approach
would again appear to turn on the intended use of the product and the claims
that are made in connection with its sale. The National Institutes of Health
(NIH), oce of Alternative Medicine (OAM, the predecessor organization to
NCCAM) and the FDA sponsored a symposium between 14 and 16 December
1994 to consider these very points. The FDA's position on the matter at the
time has been reported as follows42:
...herbs are in the Category of \dietary supplements" and can be marketed
freely as long as there is no medicinal claim made on the label. If there is a claim
then it is illegal to market the product unless it has been approved as either an
Over the Counter or Prescription drugs...The main example of herbal medicine
that was debated was garlic. Proponents of herbs argued that if garlic is useful
to lower cholesterol then it would suddenly become a drug. The FDA countered
by saying that was true, but only if the garlic was available in bottles with labels
that claimed that it was eective for lowering the cholesterol. In the absence of
claims on the label, the FDA indicated that they have no jurisdiction.
This is ne and dandy for the easy cases but inadequate for the harder
ones. Translated into plain English, the denition of \dietary supplement" in
42See http://www.acupuncture.com/News/FDA.htm. The site is devoted to the promo-
tion of alternative oriental medicine, and the report should be read in that light. The
FDA's regulations published on 6 January 2000 (infra), however, remain consistent
with the summary.
20x 321()(2) is patently unsatisfactory: it it's not a capsule or meal substitute,
then it's a dietary supplement if its labeled as a dietary supplement. The deni-
tion, with respect, begs the question43. The question, however, remains critical
because qualication of an article as a \dietary supplement" permits certain
types of health-related claims to be made that may not be ordinarily made in
relation to ordinary food.
On January 6, 2000, the FDA published its nal rule on structure/function
claims for dietary supplements44. The rule prohibits express and implied disease
claims. Implied claims include those made through the name of the product, its
formulation, or pictures. Non-disease claims pertaining to health generally or ef-
fects not associated to a specic disease, such as weight loss or muscle relaxation,
are permitted. Some clarication has also been provided on the gray distinc-
tion between structure/function claims and disease claims. Claims relating to
certain minor conditions associated with menopause or pregnancy have been
permitted, while claims relating to serious conditions are not. Manufacturers
are required under existing regulations to keep on le evidence substantiating
the claims they make in relation to a product. The requirement to print a dis-
claimer stating that the FDA has not approved the product and that it is not
43Similar diculties were encountered in relation to Merck's drug
Mevacor. The active ingredient in the drug, lovastatin was simi-
lar or identical to a product made from a fungus fermented on red
yeast rice and claiming to lower cholesterol. See Arnold I Friede,
Dietary Supplements: Background For Dialogue Between The Industry And The Medical Profession,
53 Food & Drug L.J. 413, 418.
4421 C.F.R x 101, 65 Fed. Reg. 999-1050 (January 6, 2000). The actual guidelines
are available at http://vm.cfsan.fda.gov/lrd/fr000106.html. The FDA's press release
is available at http://vm.cfsan.fda.gov/lrd/tpdsclm.html.
21a drug also stands45.
What does this all mean? For a prospective distributor or manufacturer of
Chinese traditional medicine it means he has three options. He may choose to
label it as a savory instant beverage product and put it on the same supermarket
shelf as Lipton's Cup-A-Soup. Alternatively, he can call it a dietary supplement
by labeling as such, make the strongest claim he dares without attracting the
FDA's attention and state specically on the label that it is unapproved and not
a drug. Lastly, he can expend the money needed to demonstrate, in accordance
with the FDA's regulations, its eectiveness in clinical trials, try to patent the
formula (he will probably fail if is a naturally occurring substance), and market
it as a drug.
A Game of Chess: The Impact of Strategic Behavior on Marketing Strategies
This trinity of choices regulates a triangle of competing tensions. First,
in making purchasing decisions, consumers have an interest in having the best
information about the nutritional value and physiological impact of the products
(whether food or drug) on the market. Second, the legal right to supply that
information is determined by the classication of the product as food, drug
or dietary supplement. The third prong of this devil's pitchfork bridges these
two tensions: the availability of valuable information turns not on its objective
45x 343(r)(6)(C) provides that any claim made on the label of a dietary supplement
must be accompanied by the words \This statement has not been evaluated by the
Food and Drug Administration. This product is not intended to diagnose, treat, cure
or prevent any disease."
22accuracy but on the manufacturer's decision, as a matter of economic feasibility
and corporate strategy, whether to jump through the hoops the FDA sets before
it as a precondition to the legal right to those claims.
The upshot of all this is to trap pharmaceutical companies in somewhat of a
prisoner's dilemma. Say corporation A discovers that compound X, a naturally
occurring substance, as an objective fact, cures disease Y, to which there is no
known existing cure. Before corporation A can sell compound X making the
claim that it cures disease Y, it has to obtain pre-market approval of compound
X as a new drug under x 355 of the FDCA. Today, such a process can cost up to
an average (per approved drug) of $500 million and take, from Phase I to Phase
III, an average of 12 to 15 years46 to complete. If corporation A can establish in
clinical trials the eectiveness of compound X and obtain FDA approval of the
processed compound, it can market the processed compound as a drug designed
to cure disease Y.
There is nothing under the current regulations, however, to prevent corpo-
ration B from marketing a competing product that contains compound X as an
active ingredient as a dietary supplement, provided it does not make the specic
claim that it can cure disease Y. Corporation B, by electing not to establish the
eectiveness of its particular product in relation to disease Y by undertaking
expensive clinical trials, can aord to vastly undercut the price of corporation
A's drug while drawing substantial benets from the publicity associated with
the common active ingredient. As more companies catch on to the trend, cor-
46Pharmaceutical Research and Manufacturers of America (PhRMA),
Pharmaceutical Industry 1999 Prole, Ch. 2. The publication is available online at
http://www.phrma.org/publications/industry/profile99/index.html
23poration A's product will be crowded from the market, vastly diminishing the
product's eective life, already so drastically curtailed by the unsatisfactory cur-
rent rules on the start date of drug patents47. This was, in fact, the experience
of the pharmaceutical industry in relation to Omega-3 fatty acids.
The eect is to deter corporations like corporation A from seeking to estab-
lish the scope of application of natural substances save where they are condent
of both identifying the active ingredient and synthesizing it in a manner capable
of proprietary protection. Even if it succeeds in doing so, capture of market share
will depend on consumers' willingness to pay the premium for the synthesized
product, which in turn depends on establishing through even more expensive
clinical trials the superiority of the synthesized drug. Electing to synthesize the
active ingredient also has inherent risks: side eects and contraindications may
be greater than in the natural product.
In short, the current regulatory structure does not confer sucient incen-
tives to pharmaceutical companies to experiment with naturally occurring sub-
stances. The current state of aairs gives rise to socially and economically
important questions that will be addressed in the remainder of this paper.
Checkmate: Social and Economic Implications of Current Regulation
The current state of aairs has two possible social eects, both of which are
ip sides of the same coin. The rst is emotionally appealing argument: that
as matters stand, consumers may be deprived of potentially life-saving or pain-
47Notwithstanding the passing of the Patent Term Restoration Act in 1984, the
duration of the testing, review and approval process for new drug applications (NDAs)
continues to surpass the 5 year extension given by Congress.
24relieving products because on the one hand pharmaceutical companies have no
incentive to develop traditional remedies and on the other hand dietary supple-
ments manufacturers have no right to advertise arguably valid claims48. In view
of the documented eectiveness of herbal remedies outside America, there are
real reasons to believe that genuinely eective products are being kept from con-
sumers because pharmaceutical companies consider themselves too vulnerable
to piracy from the dietary supplements sector to undertake the eort of estab-
lishing their eectiveness. One possible reform to address this concern might be
greater deregulation of the dietary supplements market to permit advertisement
of disease-related claims for herbal remedies across the board.
The contrary argument, however, is that deregulation of the dietary supple-
ments market threatens to magnify the incidence of consumer fraud and the
consumption of dangerous products based on unproven claims. In 1996, for
example, as many as 17 deaths and 800 illnesses associated with protracted or
heavy ingestion of the substance ephedrine (a naturally occurring substance de-
rived from the Chinese medicinal herb \ma huang") were reported. The FDA
issued a press release49 cautioning consumers not to use dietary supplements
containing ephedrine on the basis of claims spelt out in product labels claiming
the substance could \produce such eects as euphoria, increased sexual sen-
sations, heightened awareness, increased energy". The FDA, taking the view
that such representations violated the permissible limits for claims that could
48This in turn raises a Constitutional question, outside the scope of this pa-
per but treated elsewhere, whether consumers have a right to information regard-
ing those claims as a matter of commercial speech. See Melinda Ledden Sidak,
Dietary Supplements and Commercial Speech, 48 Food & Drug L.J. 441.
49See FDA website at http://www.fda.gov/bbs/topics/NEWS/NEW00531.html
25be made under the Dietary Supplements Act, warned that clinically signicant
eects such as heart attack, stroke, seizures, psychosis and death might result.
An additional concern is that patients might misdiagnose themselves, result-
ing in delayed treatment when they take the herbal remedy where a more drastic
procedure might be appropriate. Addressing concerns of these types involves
the opposite type of proposal: tighter enforcement of the Dietary Supplements
Act or stricter regulation of the products that can be sold or the types of claims
that may be made.
Turning to the economic concerns, one dilemma relates to the migration,
here and abroad, of consumers from expensive pharmaceuticals to natural sub-
stances. For reasons already discussed, this trend threatens to unproductively
aggravate the bifurcation of the medicinal remedies market along the lines of
the drug/dietary supplement distinction. From the economists' viewpoint, the
opportunities for rent-seeking inherent in the existing structure threaten to oblit-
erate a useful contribution to the American economy.
Interestingly, both social and economic concerns can be addressed by a third
proposal, that is, to require that once any company has established the eec-
tiveness of the herbal compound to the FDA's satisfaction, that all products
containing the active ingredient in the herbal compound be sold by prescrip-
tion only. This would have two consequences. First, it would force dietary
supplement manufacturers to undergo the formal pre-market approval process,
whether or not they desired to make the disease-related claims, thus eliminat-
ing any economic rents from their strategic behavior. At the same time, the
26approval process would abate the likelihood of fraudulent claims while the re-
quirement that the drug be sold by prescription would reduce the possibility
of misuse. The theoretical objective of such an exercise would be to produce a
level playing eld for pharmaceutical companies and dietary supplement man-
ufacturers in the context where a herbal ingredient demonstrates the ability to
treat disease.
The downside of this proposal is that it would raise the unit cost of herbal
drugs across the board, an eect that militates directly against another, equally
important, economic concern. It has already been argued that existing Federal
policy, in its attempt to protect consumers from the potential dangers of herbal
remedies without depriving them of their potential benets, does so at the
risk of critical long-term economic consequences to America's position in the
international pharmaceutical market. However, any proposal that attempts to
rework this compromise by making herbal drugs more costly also reduces the
international marketability of those drugs, particularly in China. Perhaps more
importantly, such a proposal would fail to address the trade issues examined in
the next section.
Truth or Dare: Trade Issues Raised by Claims-Verication Methods under the FDCA
To make a specic disease-related claim under current legislation, the man-
ufacturer of a product must satisfy, as interpreted by the FDA, the statutory
provisions relating to food and drugs. Where food is concerned, a claim \char-
acteriz[ing] the relationship of any nutrient [contained in the food and required
27to be disclosed on the food label under 21 U.S.C. x 343 (q)(1) or (2)] to a disease
or health-related condition" may only be made if
(1)
The Secretary promulgates regulations for the making of such claims, hav-
ing determined, \based on the totality of publicly available scientic evidence
(including evidence from well-designed studies conducted in a manner which is
consistent with generally recognized scientic procedures and principles), that
there is signicant scientic agreement, among experts qualied by scientic
training and experience to evaluate such claims, that the claim is supported by
such evidence and the manufacturer complies with such regulations50"; and
(2)
The food does not contain, as determined by the Secretary \any nutrient in
an amount which increases to persons in the general population the risk of a
disease or health-related condition which is diet related, taking into account the
signicance of the food in the total daily diet51".
Alternatively, a food disease prevention claim may be made without an ap-
plicable FDA regulation if it is based on an authoritative statement of a United
States public health agency or the National Academy of sciences and pre-market
notication of at least 120 days is made to the FDA52.
Insofar as drugs are concerned, the FDA must be satised of the safety
5021 U.S.C. x 343(r)(1)(B) read with x 343 (r)(3)(A)(i) and x 343(r)(3)(B)(i)
5121 U.S.C. x 343(r)(3)(A)(ii)
5221 U.S.C. x 343(r)(3)(C), introduced in 1997.
28and eectiveness of the drug in question in treating the particular disease or
condition that it purports to address. To qualify the drug for approval, the
manufacturer must:
(1)
Conduct \adequate tests by all methods reasonably applicable" to establish
that the drug is \safe for use under the conditions prescribed, recommended, or
suggested in the proposed labeling53" and
(2)
Provide \substantial evidence that the drug will have the eect it purports
or is represented to have under the [said] conditions of use54".
\
Substantial evidence" is dened in x 355(d) as \evidence consisting of ad-
equate and well-controlled investigations, including clinical investigations, by
experts qualied by scientic training and experience to evaluate the eective-
ness of the drug involved, on the basis of which it could fairly and responsibly
be concluded by such experts that the drug will have the eect it purports...".
In summary, a disease-related claim for a food product must accord with
general medical opinion; a disease-related claim for a drug must be established
by clinical trials. By way of recapitulation, disease-related claims are prohibited
for dietary supplements with the exception of diseases related to nutrient de-
5321 U.S.C. x 355(d)(1)
5421 U.S.C. x 355(d)(5)
29ciency and structure/function claims55, as claried under the FDA's nal rule of
6 January 2000, provided the manufacturer has substantiation that the claim is
truthful and not misleading56. Non-compliance with any of these requirements
constitutes \misbranding" under the FDCA.
As it stands, Chinese traditional medicines are regulated in the United States
as dietary supplements. In terms of the type of claim that may be made in
relation to these products, their status is secondary (in the sense of only weaker
claims being permitted) to both approved drugs and foods on which there is
widespread medical consensus about their role in the prevention of disease (such
as soy products). This is primarily attributable to the lack of \substantial
evidence" or \signicant scientic agreement" establishing the eectiveness of
Chinese traditional medicines in disease prevention, which disqualies them
from making those claims as either drugs or foods.
The arrangement is perfectly understandable if Chinese traditional medicines
are either treated as \new drugs" or as foods, such as high-ber/low sodium ce-
reals, which were specically designed in light of modern medical understanding
of the cause of ailments such as cancer or heart disease. The arrangement, how-
ever, is vulnerable to two specic claims that may be made by the Chinese gov-
ernment under the WTO Agreement on Technical Barriers to Trade (ATBT).
The ATBT is a specic agreement acceded to by WTO members adopting a
procedure \establishing disciplines on the preparation, adoption and applica-
tion of technical regulations, standards and conformity assessment procedures,
5521 U.S.C. x 343(r)(6)(A)
5621 U.S.C. x 343(r)(6)(B)
30that might act as technical barriers to trade57". The preamble to the ATBT58
recites two specic goals of the Agreement that are relevant to the argument.
The rst, which is more generally stated, is
\
...to ensure that technical regulations and standards, including packaging,
marking and labeling requirements, and procedures for assessment of conformity
with technical regulations and standards do not create unnecessary obstacles to
international trade;"
The second, which is of particular relevance, is
\
...that no country should be prevented from taking measures necessary...for
the protection of human, animal or plant life or health...subject to the require-
ment that they are not applied in a manner which would constitute a means
of arbitrary or unjustiable discrimination between countries where the same
conditions prevail..."
(emphasis added)
The primary fear is that it would be open to China to argue that the
fore-mentioned denitional issues and the Western-scientic bias of the claims-
57Introduction to the ATBT on the WTO website. See
http://www.wto.org/wto/goods/tbtindex.htm
58The full text of the Agreement is available at
http://www.wto.org/wto/goods/tbtagr.htm.
31verication methodology under the FDCA (both of which may be considered
\procedures for assessment of conformity with technical regulations") consti-
tute \a means of arbitrary or unjustiable discrimination". The thrust of the
argument would be the premise that the claims verication methodology of Chi-
nese traditional medicine { namely the \trial-and-error" or \anecdotal evidence"
method - is no less valid as a means of determining the accuracy of disease-
related claims (i.e. \label requirements"). Furthermore, since the FDCA's de-
nitions of \food", \drug" and \dietary supplement" are based on intended use,
and therefore strongly associated with the types of claims that can be made,
these provisions would also be vulnerable to criticism.
Neither the importance of Chinese traditional medicine as a trade issue to
China nor China's willingness to raise it in trade talks should be underesti-
mated. On 22 July 1999, China and Singapore formally signed a Memorandum
of Understanding \to formalize bilateral coordination, liaison and cooperation
in Traditional Chinese Medicine"59. Although China has yet to raise these is-
sues with the United States, it is not inconceivable, given the desire of United
States pharmaceutical companies to increase exports to China and the growing
demand within the United States for oriental medicines, that it will be ad-
vanced either in bilateral trade negotiations or as a condition for open markets
in WTO talks. A more urgent concern for pharmaceutical companies is that
such a development could also supply the dietary supplements industry with a
vital opportunity to strengthen its position within the regulatory framework.
59Singapore Ministry of Health Press Release, 22 July 1999. See
http://www.gov.sg/moh/releases/mou.html
32Segue: The Sixty-Four Thousand Dollar Question
To bring these issues into focus, the question raised here is whether the
current regulatory structure, or the proposed \prescription only" alternative,
strikes the only acceptable (albeit unsatisfactory) balance between these several
competing factors. Is there a way to supply safe and eective herbal remedies
to consumers, on a level playing eld, in accordance with existing trade Con-
ventions, without increasing their cost dramatically? The answer, particularly
in the context of Chinese traditional medicine, would appear to be that there
is.
As contradistinct from modern alternative medicines, in the eld of Chinese traditional medicine the economic and social arguments in favor of deregulation are amplied while the social concerns over fraud and misuse are downplayed. This is attributable to a single factor, namely that many claims made in connection with Chinese traditional medicine have already been documented by millennia of trial-and-error medical practice. Accordingly, there is real reason to believe that Chinese medicines are actually safe and eective in the prevention or cure of disease, notwithstanding the lack of scientic, clinical evidence and that existing regulations might be blocking economic progress without social justication. If, therefore, manufacturers could obtain approval to make disease-related claims by submitting to the FDA an alternative, less expensive, but not qualitatively inferior, means of proof, all the highlighted concerns might be addressed under a single proposal for reform.
You Say Po-tay-to, I Say Po-tah-to: Diering Philosophical Approaches to the Healing Art
[
The main idea underlying Chinese traditional healing60 is that specic ill-
nesses are attributable to disruptions of a force that runs through all living
things, the \Qi" (pronounced \chee") or \vital substance". This tenet is part
of a larger philosophical concept, that of the \Tao" or the path all living things
obey in following their true natures. The \Tao" advocates a lifestyle of simplic-
ity, moderation and balance. This balance is represented by the \Yin-Yang"
symbol:
\
60See generally Carol Hart, Ph.D. & Magnolia Goh, L.Ac.,
Traditional Chinese Medicine (1997), and Jason Elias L.Ac. & Katherine
Ketcham, The Five Elements of Self-Healing (1998), and William Collinge, Ph.D.,
Alternative Medicine (1996).
33Yin" and \Yang" are descriptions of complementary opposites in things liv-
ing and nonliving. In Chinese thought, equilibrium in the \Yin" and \Yang"
dualism is not achieved by the competition of opposing forces, but by modera-
tion. Deviation from the \Tao" { excessive drinking, eating, wealth or pleasure
{ causes blockages in the body through which \Qi" energy ows. Chinese tradi-
tional medicine seeks, by procedures such as acupuncture, massage, and the use
of herbal medicines, to restore imbalances by removing these blockages. One
of the most remarkable diagnostic techniques developed by Chinese medicine
is \pulse analysis". A skilled practitioner of this art can distinguish hundreds
of variations of pulse, measured by pulse width, depth, strength, \quality" and
rhythm, and determine from the pulse alone the particular disease that ails the
patient61. In contrast to Western medicine, the objective of which is to identify
a particular chemical, hormonal or biological imbalance and to treat the symp-
tom with a counteracting drug or procedure, the Chinese medicinal technique
is described as \holistic" and \non-intrusive". Modern practitioners of Chinese
medicine advocate it not as alternative, but complementary to Western science.
The belief is that
Western medicine acts upon the Yin of the body, the substance of the body,
the actual cells and chemicals. Oriental medicine works more on the energy that
animates those cells.
What Western medicine tends to diagnose and treat is the eect that the
61See Hart & Goh, ibid. at pages 50 to 52.
34disease state has on the body itself. The Practitioner of Oriental medicine
diagnoses and acts upon the energy that creates the disease state62.
While these ideas may appear strange from a Western scientic viewpoint,
the philosophy has a strong following today in both China and the United States.
More importantly, however, the specic preventive and curative claims of par-
ticular herbs or herb combinations have been validated by the \trial-and-error"
method (also referred to as the \anecdotal evidence" or \bibliographical evi-
dence" methods) of ascertaining drug safety and eectiveness. These methods
have a long pre-modern scientic history. The seminal text on Chinese medicinal
healing, for example, The Yellow Emperor's Classic of Medicine, was written
in the 2nd century, BC. Unlike the clinical laboratory testing mandated by the
FDA, the anecdotal evidence method depends on the administration of natu-
ral compounds to numerous patients over long periods of time. The patients'
reactions to the compounds can be recorded, forming a history of medicinal
application for these compounds. Over time, it is possible to determine what
natural substances work best in what combinations for a given disease or dis-
eases.
In a worldwide survey of the regulation of herbal remedies published in
199863, the WHO, in reporting that \[t]he use of herbal medicines in the USA
is less widespread than in the majority of developed nations," also noted that
62Al Stone, L.Ac., Western and Eastern Medicine Compared (internet article) at
http://www.acupuncture.com/Acup/Comparison.html
63Traditional Medicine Programme, World Health Organization,
Regulatory Situation of Herbal Medicines: A Worldwide Survey (1998)
35\...the FDA does not accept bibliographic evidence of eectiveness, but prefers
randomized controlled trials as evidence of ecacy". By comparison, in France,
the criterion for the registration of \vegetable drugs" includes \historical proof of
their widespread traditional use and their well established use in self-medication64".
Bibliographic evidence is also accepted as basis for registration in Germany,
where a survey found that 85% of the German population \believed that the
experience of physicians, practitioners, and patients should be accepted as a
proof for the ecacy of natural medicines65". In Switzerland, herbal remedies
are permitted registration under an abridged application process requiring less
clinical testing66.
It is arguable that the anecdotal testing methodology is in fact not funda-
mentally unlike clinical trials { administer the compound to the test patient and
observe his reaction to it. Of course we have no idea whether the ancient Chinese
tests were conducted double blind against placebos. We also lack data on sam-
ple size and uniformity of test subjects. There is no specic chemical analysis
of the precise physiological eect of the compound from which projections can
be made about adverse reactions with other drugs or foods. The absence of raw
data, however, does not disqualify the compound as either \unsafe" or \ineec-
tive". On the contrary, the anecdotal method's greatest strength counteracts
the greatest shortcoming of the FDA-sanctioned clinical method, namely that




36population, for it is only then that (statistically speaking) undetectable adverse
reactions and contraindications are revealed. Although the FDA requires exten-
sive pre-marketing testing, it relies heavily on post-marketing surveillance. The
Center for Drugs implicitly recognized the shortcomings of the current approval
methodology when it created in 1998 a new Oce of Post-Marketing Drug Risk
Assessment.
In 1998 itself, 177 prescription and 88 over-the-counter drugs were recalled.
The average number of recalls over the six-year period from 1993 to 1998 came
to 233.5 recalls of prescription drugs and 71.67 recalls of over-the-counter drugs
annually67. According to a May 10, 1999 FDA Report68, unanticipated serious
adverse events are occurring at a lower rate between 1994 and 1997 than between
1976 and 1985. The statistical data, however, is troubling. Between 1994 and
1997, 30.3% of new molecular entities underwent signicant post-approval label
changes. While this gure compared favorably to 51.5% in the earlier period, it
does mean that between ? and 1
2 of new drugs released in the United States in
the last quarter century were seriously or signicantly inaccurately labeled on
their release date. The 1999 Report observes69:
Although the 30-percent proportion is better than that previously found, it
still raises the question of why these serious risks are not discovered before mar-
67Center for Drug Evaluation and Research, Food and Drug Administration, U.S.
Department for Health and Human Services, 1998 Report to the Nation, at pp. 26-27,
available online at http://www.fda.gov/cder/reports/rptntn98.pdf
68Food and Drug Administration, U.S. Department for Health and Human Services,
Managing the Risks from Medical Product Use: Creating a Risk Management Framework,
at pp. 35-36, available online at http://www.fda.gov/oc/tfrm/riskmanagement.pdf
69Ibid. at page 36
37keting. There are several reasons for this. For example, some kinds of serious
side eects, such as those resulting from drug overdoses, cannot be studied ethi-
cally in humans and can only be learned about from overdoses of drugs that are
on the market. In addition, in some cases, the Agency approves drugs intended
to treat serious and life-threatening diseases with less information than usual,
knowing that more will be learnt in the post-marketing period. Finally...it is
impossible to detect or predict before medical product approval every possible
drug interaction, unusual clinical situation or rare side eect that could lead to
harm once a product is on the market.
Whereas there is no comparable data available for Chinese traditional medicines,
a strong case can be built on the fact that these herbal remedies are not sub-
ject to the uncertain period of random testing that commences with the initial
release of new drugs. Unlike new drugs and new dietary supplements, these
medicines have already been \tried and tested", their safety and eectiveness
established by thousands of years of medical practice.
The fact is that China maintains a male life expectancy of 69.57 years com-
pared to that of 72.95 years in America despite spending only a fraction of
what America does on health care on four times the number of people70. What
relationship does this bear to the fact that China is a market, by WHO's esti-
mation, 30-50% dependent on Chinese traditional medicines, the vast majority
of which are not available to consumers in America? All the more remarkable
is that this takes place notwithstanding the documented inability of Chinese
70CIA World Factbook 1999
38production facilities to comply with Good Manufacturing Practices or produce
safe medications. For example, between 1997 and 1999, twenty-two medicines
sold in processed form were prohibited from import into Singapore on the ba-
sis of containing poisonous substances or toxic metals such as lead or mercury
beyond safe levels71. The incidence of death or shortening of life due to the
lack of product safety may well account for the marginal dierence in life ex-
pectancy. It is my submission that Chinese traditional medicines should not
be subject to the same precautionary safeguards as new drugs when there is no
empirical evidence to show that those safeguards are more eective in protecting
consumers or guaranteeing eectiveness than the (historically) more established
trial-and-error system.
The trial-and-error method of proof is already widely accepted in Europe. In
fact, Congress appeared to mandate a step in the direction of accepting Euro-
pean anecdotal evidence in 1997 when it passed x 803(c)(2) of the Food and Drug
Administration Modernization Act. That section requires the FDA to support
a move towards the acceptance of mutual recognition agreements between the
European Union and the United States. Similarly, x 803(c)(3) requires regular
FDA participation in meetings with foreign governments to discuss methods of
harmonizing regulatory requirements. Thus, for example, if the United States
were to admit pharmaceuticals the use of which has been approved in France
or Germany, it would eectively be permitting back-door registration of herbal
drugs by bibliographic evidence, since that is a valid method of proof in those
71Singapore Ministry of Health press releases, 1997-1999.
39countries.
A Time to Kill, and A Time to Heal72: Closing Case and Proposals for Reform
If Chinese traditional medicines are an established complement to Western
medicine as a means of treating diseases, then the question why American con-
sumers ought to be deprived of the information necessary to make an informed
choice as to the proper and eective use of those drugs demands attention. This
is particularly so given the FDA's strong emphasis on curative medicine. Under
the FDA's priority approval system, life-critical drugs (such as AIDS or cancer
drugs) receive the most attention. Drugs aimed at preventing disease receive
very low priority, so much so that promotion of the preventive science has fallen
almost exclusively to the hands of the dietary supplements sector.
If, additionally, the economic concerns that have been highlighted in this pa-
per are not illusory but genuine, then the case for action is strengthened further.
America needs to address the signicant issues raised by the disparate regula-
tory treatment of two classes of products (drugs and dietary supplements) that
Americans treat as a single consumer market (medicines). It is also clear that
the American pharmaceutical industry needs to rethink its economic strategy
for China, and that Congress must determine if the regulatory structure for
pharmaceutical companies is sucient to confront the challenges ahead.
Finally, if the anecdotal evidence method of proof is a viable alternative
72Ecclesiastes 3:3
40to the established means under current regulation, then there is no reason why
reform should not be initiated { it only remains to ask what the nal structure of
the reform proposal might look like. The principal tasks would be the empirical
matter of identifying the shortcomings of the anecdotal evidence system and
compensating for them, and the administrative matter of creating a system for
the review and approval of products. Implementing a broad proposal for reform
would therefore require the conduct of feasibility studies in several areas:

Denition of dietary supplements for which disease-related claims may be
made upon submission of satisfactory bibliographic evidence, or a combination
of bibliographic and clinical evidence;

Alternatively, classication of certain herbal remedies as drugs through a
procedure (as in France and Germany) for pre-market review of bibliographic
evidence or (as in Switzerland) a combination of bibliographic and clinical evi-
dence;

Development of administrative procedures for submission of bibliographic
evidence to the FDA under either proposal;

41Development of administrative procedures for compilation and analysis of
evidence in relation to specic claims by FDA under either proposal;

Investigation of suciency of evidence in demonstrating safety and eciency;

Possible mandating of supplementary testing under clinical conditions e.g.
relating to toxicity and dosage;

Determination of what types of herbal remedies may be sold openly (self-
diagnosis) and what type must be sold by prescription;

Uniform inter-state procedures for qualication of Oriental Medicine Prac-
titioners for the prescription and sale of herbal remedies; or

Alternatively, provision for sale of prescription herbal remedies through phar-
macies.
It is hoped, through the arguments oered here, that sucient interest will
be generated to initiate discussion about the issues at stake. It is my submission
42that they merit utmost attention if the United States is to remain a serious
contender in the international pharmaceuticals market in the 21st century.
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